Treatment of renal cell carcinoma with interferons

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Renal cell carcinoma (RCC) is considered to be an immunogenic cancer. RCC is refractory to chemotherapy and radiation. Immunotherapy including interferon (IFN)-alpha, gamma and interleukin-2 are the treatment of choice for metastatic RCC. IFN-alpha is most widely used in Japan. The response rate of IFN-alpha is 10-20 %. Lung lesions and lymphnodes are the usual effective sites. The survival benefit of IFN-alpha in patients with metastatic RCC has been shown in prospective randomized studies. Nephrectomy is recommended before interferon therapy if the patients have good performance status. Adjuvant interferon therapy failed to show any survival benefit after curative excision of primary RCC. The place of IFN-alpha is going to be changed due to the recent use of molecular targeting drugs.

Original languageEnglish
Pages (from-to)1281-1285
Number of pages5
JournalNippon rinsho. Japanese journal of clinical medicine
Volume64
Issue number7
Publication statusPublished - 2006 Jul

Fingerprint

Renal Cell Carcinoma
Interferon-alpha
Interferons
Therapeutics
Survival
Drug Delivery Systems
Nephrectomy
Immunotherapy
Interferon-gamma
Interleukin-2
Japan
Prospective Studies
Radiation
Drug Therapy
Lung
Neoplasms

Cite this

Treatment of renal cell carcinoma with interferons. / Oya, Mototsugu.

In: Nippon rinsho. Japanese journal of clinical medicine, Vol. 64, No. 7, 07.2006, p. 1281-1285.

Research output: Contribution to journalArticle

@article{9085ef4f092b43f7acdde4be8e9b8c8b,
title = "Treatment of renal cell carcinoma with interferons",
abstract = "Renal cell carcinoma (RCC) is considered to be an immunogenic cancer. RCC is refractory to chemotherapy and radiation. Immunotherapy including interferon (IFN)-alpha, gamma and interleukin-2 are the treatment of choice for metastatic RCC. IFN-alpha is most widely used in Japan. The response rate of IFN-alpha is 10-20 {\%}. Lung lesions and lymphnodes are the usual effective sites. The survival benefit of IFN-alpha in patients with metastatic RCC has been shown in prospective randomized studies. Nephrectomy is recommended before interferon therapy if the patients have good performance status. Adjuvant interferon therapy failed to show any survival benefit after curative excision of primary RCC. The place of IFN-alpha is going to be changed due to the recent use of molecular targeting drugs.",
author = "Mototsugu Oya",
year = "2006",
month = "7",
language = "English",
volume = "64",
pages = "1281--1285",
journal = "Nihon rinsho. Japanese journal of clinical medicine",
issn = "0047-1852",
publisher = "Nipponrinsho Co., Inc.",
number = "7",

}

TY - JOUR

T1 - Treatment of renal cell carcinoma with interferons

AU - Oya, Mototsugu

PY - 2006/7

Y1 - 2006/7

N2 - Renal cell carcinoma (RCC) is considered to be an immunogenic cancer. RCC is refractory to chemotherapy and radiation. Immunotherapy including interferon (IFN)-alpha, gamma and interleukin-2 are the treatment of choice for metastatic RCC. IFN-alpha is most widely used in Japan. The response rate of IFN-alpha is 10-20 %. Lung lesions and lymphnodes are the usual effective sites. The survival benefit of IFN-alpha in patients with metastatic RCC has been shown in prospective randomized studies. Nephrectomy is recommended before interferon therapy if the patients have good performance status. Adjuvant interferon therapy failed to show any survival benefit after curative excision of primary RCC. The place of IFN-alpha is going to be changed due to the recent use of molecular targeting drugs.

AB - Renal cell carcinoma (RCC) is considered to be an immunogenic cancer. RCC is refractory to chemotherapy and radiation. Immunotherapy including interferon (IFN)-alpha, gamma and interleukin-2 are the treatment of choice for metastatic RCC. IFN-alpha is most widely used in Japan. The response rate of IFN-alpha is 10-20 %. Lung lesions and lymphnodes are the usual effective sites. The survival benefit of IFN-alpha in patients with metastatic RCC has been shown in prospective randomized studies. Nephrectomy is recommended before interferon therapy if the patients have good performance status. Adjuvant interferon therapy failed to show any survival benefit after curative excision of primary RCC. The place of IFN-alpha is going to be changed due to the recent use of molecular targeting drugs.

UR - http://www.scopus.com/inward/record.url?scp=33748752243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748752243&partnerID=8YFLogxK

M3 - Article

C2 - 16838645

AN - SCOPUS:33748752243

VL - 64

SP - 1281

EP - 1285

JO - Nihon rinsho. Japanese journal of clinical medicine

JF - Nihon rinsho. Japanese journal of clinical medicine

SN - 0047-1852

IS - 7

ER -